Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background

Journal of Clinical Investigation

Volumn 104, Issue 6, 1999, Pages 687-695

  Onda, Hiroaki ^a   Lueck, Andreas ^a   Marks, Peter W ^a   Warren, Henry B ^b   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GELSOLIN;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CYSTADENOMA; EMBRYO; GENE MUTATION; GENOTYPE; KIDNEY TUMOR; LIVER HEMANGIOMA; LIVER TUMOR; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBEROUS SCLEROSIS;

EID: 0032741978     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7319     Document Type: Article

References (36)

1. Gomez, M., Sampson, J., and Whittemore, V. 1999. The tuberous sclerosis complex. Oxford University Press. Oxford, United Kingdom. 340 pp.
2. Henske, E.P., et al. 1997. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the parhogenesis of tuberous sclerosis tumors. Am. J. Pathol. 151:1639-1647.
3. Henske, E.P., et al. 1996. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am. J. Hum. Genet. 59:400-406.
4. Carbonara, C., et al. 1996. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer. 15:18-25.
5. Green, A.J., Smith, M., and Yates, J.R. 1994. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat. Genet. 6:193-196.
6. The European Chromosome 16 Tuberous Sclerosis Consortium. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 75:1305-1315.
7. van Slegtenhorst, M., et al. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 277:805-808.
8. Xiao, G.H., Shoarinejad, F., Jin, F., Golemis, E.A., and Yeung, R.S. 1997. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J. Biol. Chem. 272:6097-6100.
9. Wienecke, R., Konig, A., and DeClue, J.E. 1995. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J. Biol. Chem. 270:16409-16414.
10. Tsuchiya, H., Orimoto, K., Kobayashi, K., and Hino, O. 1996. Presence of potent transcriptional activation domains in the predisposing tuberous sclerosis (Tsc2) gene product of the Eker rat model. Cancer Res. 56:429-433.
11. Soucek, T., Yeung, R.S., and Hengstschlager, M. 1998. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad. Sci. USA. 95:15653-15658.
12. Henry, K.W., et al. 1998. Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J. Biol. Chem. 273:20535-20539.
13. van Slegtenhorst, M., et al. 1998. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7:1053-1058.
14. Plank, T.L., Yeung, R.S., and Henske, E.P. 1998. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res. 58:4766-4770.
15. Young, J.M., et al. 1998. A mutation screen of the TSC1 gene reveals 26 protein truncating mutations and 1 splice site mutation in a panel of 79 tuberous sclerosis patients. Ann. Hum. Genet. 62:203-213.
16. Kwiatkowska, J., et al. 1998. Comprehensive mutational analysis of the TSC1 gene: observations on frequency of mutation, associated features, and nonpenetrance. Ann. Hum. Genet. 62:277-285.
17. Jones, A.C., et al. 1999. Comprehensive mutation analysis of TSC1 and TSC2 and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 64:1305-1315.
18. Eker, R., Mossige, J., Johannessen, J.V., and Aars, H. 1981. Hereditary renal adenomas and adenocarcinomas in rats. Diagn. Histopathol. 4:99-110.
19. Yeung, R.S., et al. 1994. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl. Acad. Sci. USA. 91:11413-11416.
20. Kobayashi, T., Hirayama, Y., Kobayashi, E., Kubo, Y., and Hino, O. 1995. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat. Genet. 9:70-74.
21. Witke, W., et al. 1995. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell. 81:41-51.
22. Azuma, T., Witke, W., Stossel, T.P., Hartwig, J.H., and Kwiatkowski, D.J. 1998. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J. 17:1362-1370.
23. Lueck, A., Brown, D., and Kwiatkowski, D. 1998. The actin-binding proteins adseverin and gelsolin are both highly expressed but differentially localized in kidney and intestine. J. Cell Sci. 111:3633-3643.
24. Everitt, J., Goldsworthy, T., Wolf, D., and Walker, C. 1992. Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. J. Urol. 148:1932-1936.
25. Kubo, Y., et al. 1995. Allelic loss at the tuberous sclerosis (Tsc2) gene locus in spontaneous uterine leiomyosarcomas and pituitary adenomas in the Eker rat model. Jpn. J. Cancer Res. 86:828-832.
26. Kobayashi, T., et al. 1999. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 59:1206-1211.
27. Shepherd, C.W., Scheithauer, B.W., Gomez, M.R., Altermatt, H.J., and Katzmann, J.A. 1991. Subependymal giant cell astrocytoma: a clinical, pathological, and flow cytometric study. Neurosurgery. 28:864-868.
28. Ewalt, D.H., Sheffield, E., Sparagana, S.P., Delgado, M.R., and Roach, E.S. 1998. Renal lesion growth in children with tuberous sclerosis complex. J. Urol. 160:141-145.
29. Al-Saleem, T., et al. 1998. Malignant rumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83:2208-2216.
30. Sampson, J.R., Patel, A., and Mee, A.D. 1995. Multifocal renal cell carcinoma in sibs from a chromosome 9 linked (TSC1) tuberous sclerosis family. J. Med. Genet. 32:848-850.
31. Yeung, R.S., Katsetos, C.D., and Klein-Szanto, A. 1997. Subependymal asrrocytic hamartomas in the Eker rat model of tuberous sclerosis. Am. J. Pathol. 151:1477-1486.
32. Kinzler, K., and Vogelstein, B. 1998. Familial cancer syndromes: the role of caretakers and gatekeepers. In The genetic basis of human cancer. B. Vogelstein and K. Kinzler, editors. McGraw-Hill. New York, NY. 241-242.
33. Shieh, D.B., et al. 1999. Cell motility as a prognostic factor in stage I nonsmall cell lung cancer: role of gelsolin expression. Cancer. 85:47-57.
34. Dosaka-Akita, H., et al. 1998. Frequent loss of gelsolin expression in nonsmall cell lung cancers of heavy smokers. Cancer Res. 58:322-327.
35. Asch, H.L., et al. 1996. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res. 56:4841-4845.
36. Tanaka, M., et al. 1995. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res. 55:3228-3232.